Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACADIA Pharmaceuticals (ACAD) Stock Price & Analysis
2,196 Followers
ACAD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.55 - $32.59
Previous Close$17.75
Volume80.70K
Average Volume (3M)1.73M
Market Cap
$2.95B
Enterprise Value$2.45B
Total Cash (Recent Filing)$532.46M
Total Debt (Recent Filing)$49.19M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 31, 2024EPS Estimate
$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding165,220,884
10 Day Avg. Volume1,648,770
30 Day Avg. Volume1,730,469
Standard Deviation0.15
R-Squared0.02
Alpha-0.00135
Financial Highlights & Ratios
Price to Book (P/B)7.14
Price to Sales (P/S)10.94
Price to Cash Flow (P/CF)21.70
P/FCF Ratio21.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.01
Enterprise Value/Gross Profit3.58
Enterprise Value/Ebitda157.75
Forecast
1Y Price Target
$27.88Price Target Upside56.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
ACADIA Pharmaceuticals News
PremiumCompany Announcements
ACADIA Pharmaceuticals Holds Successful 2024 Annual Meeting
Bulls Say, Bears Say
Bulls Say
Financial StabilityShares present a favorable setup on stabilizing Daybue revenues or a positive pipeline readout.
Market OpportunityInvestors may be overlooking the greater than $4 billion opportunity for ACP-204 in Alzheimer’s disease psychosis.
Product PerformanceConcerns over Daybue may be overshadowing an impressive launch with 25% of the Rett population treated since March 2023 approval.
Bears Say
EarningsInvestors will likely be disappointed by 1Q24 Daybue sales of $75.9M, which modestly missed Consensus' lower reset expectation of $79.0M due to unexpected seasonal trends in early 1Q24.
Investor SentimentDaybue trends continue to face intense investor scrutiny due to its gastrointestinal side effect profile.
Product PerformanceThe absolute number of patients discontinuing Daybue was higher than new additions, impacting net patients on the drug.
---
Ownership Overview
51.75% Insiders
18.76% Mutual Funds
16.93% Other Institutional Investors
12.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.55 and its highest was $32.59 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on May 08, 2024. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.051.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.19.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 165,220,890 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went down -11.208%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 793M.
---
ACADIA Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.88 (56.10% Upside)
$27.88 (56.10% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 679.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.37%
12-Months-Change
Fundamentals
Return on Equity
-0.41%
Trailing 12-Months
Asset Growth
30.49%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q1 2024
0:00 / 0:00
---
ACAD Stock 12 Month Forecast
Average Price Target
$27.88
▲(56.10% Upside)
Technical Analysis
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+10.05%
reiterated a buy rating 7 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +10.05% per trade.
---